Form D · Pharmaceuticals

Cristcot LLC

Concord, MA · CIK 0001715931

Offering snapshot reported Jun 6, 2025 · SEC filing

Reported sold
$10.5M
Offering amount: $55M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 25, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 6, 2025Initial$10,473,043No comparison3SEC filing
May 1, 2024Initial$6,987,025No comparison30SEC filing
Oct 23, 2019Amendment$13,728,492$10,728,492vs Sep 27, 20183SEC filing
Sep 27, 2018Initial$3,000,000No comparison1SEC filing
Sep 7, 2017Initial$411,387No comparison22SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-548328

Source: Form D, filed Jun 6, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Bartlett Director
Jennifer J. Davagian Director, Executive
John S. Davagian Director
John S. Davagian Ii Director
Mark C. Ensign Executive
Henry Kay Director
Marc Keller Director
Ernest H. Pomerantz Director
David Shepard Director
David Shepherd Director
Richard Warburg Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
9 Damonmill Square Suite 4 A
Concord, MA, 01742
Phone: 978-212-6380